Discovery & targeted metabolomics to significantly accelerate your ability to discover and validate dynamic biomarkers of health, disease, and drug response, driving better drug development.
Sapient offers industry-leading metabolomics services designed to uncover dynamic, non-genetic biomarkers that inform on disease progression, therapeutic response, and patient outcomes. Our platform combines high-throughput, untargeted metabolomics profiling with advanced biocomputational analysis to deliver actionable insights faster and at scale.
With an analytical cycle time of <1 minute per sample, we have the capacity to process thousands of samples per day for fast turnaround.
Through our in-house library of 13,000+ chemical reference standards, we can routinely provide definitive identifications for up to 1,400 metabolites in large-scale studies.
Our expertise in-house biocomputational team applies advanced analytical frameworks and machine learning to identify novel biomarkers, map pathways, and develop metabolite-driven predictive models of disease and drug response.
Our metabolomics workflows are compatible with diverse sample types, from plasma and serum to tissue, urine, CSF, cells, and media – allowing for rapid translation from early discovery through clinical trials.
Over 80% of disease risk is non-genetic. Sapient’s metabolomics services reveal the biochemical fingerprints of lifestyle, environment, and therapeutic exposure—offering a deeper understanding of human biology beyond the genome.
Download the fact sheet to see how our metabolomics services can deliver unique insights to accelerate your studies.
"*" indicates required fields
